Acknowledgments: This work was supported by the Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology 097377 to Jill King and Adilia Warris.Peer reviewedPublisher PD

Henriet, Stefanie S. V.

King, Jill

Warris, Adilia

Journal of Fungi

Patients with chronic granulomatous disease (CGD) have the highest life-time incidence of invasive aspergillosis and despite the availability of antifungal prophylaxis, infections by Aspergillus species remain the single most common infectious cause of death in CGD. Recent developments in curative treatment options, such as haematopoietic stem cell transplantation, will change the prevalence of infectious complications including invasive aspergillosis in CGD patients. However, invasive aspergillosis in a previously healthy host is often the first presenting feature of this primary immunodeficiency. Recognizing the characteristic clinical presentation and understanding how to diagnose and treat invasive aspergillosis in CGD is of utmost relevance to improve clinical outcomes. Significant differences exist in fungal epidemiology, clinical signs and symptoms, and the usefulness of non-culture based diagnostic tools between the CGD host and neutropenic patients, reflecting underlying differences in the pathogenesis of invasive aspergillosis shaped by the nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase deficiency

Jill King

Stefanie S. V. Henriet

Adilia Warris

Directory of Open Access Journals

Aspergillosis in Chronic Granulomatous Disease

Acknowledgments: This work was supported by the Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology 097377 to Jill King and Adilia Warris.Peer reviewe

Aberdeen University Research

Stefanie Henriet

Crossref

Multidisciplinary Digital Publishing Institute

Aspergillosis in Chronic Granulomatous Disease

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals

Aberdeen University Research

Crossref

Multidisciplinary Digital Publishing Institute